Exact Therapeutics As Stock Revenue
| EXTX Stock | NOK 3.78 0.06 1.56% |
Exact Therapeutics AS fundamentals help investors to digest information that contributes to Exact Therapeutics' financial success or failures. It also enables traders to predict the movement of Exact Stock. The fundamental analysis module provides a way to measure Exact Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Exact Therapeutics stock.
Exact |
Exact Therapeutics AS Company Revenue Analysis
Exact Therapeutics' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Based on the latest financial disclosure, Exact Therapeutics AS reported 0.0 of revenue. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The revenue for all Norway stocks is 100.0% higher than that of the company.
Exact Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Exact Therapeutics' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Exact Therapeutics could also be used in its relative valuation, which is a method of valuing Exact Therapeutics by comparing valuation metrics of similar companies.Exact Therapeutics is currently under evaluation in revenue category among its peers.
Exact Fundamentals
| Return On Equity | -0.46 | |||
| Return On Asset | -0.26 | |||
| Operating Margin | (844.98) % | |||
| Current Valuation | 432.68 M | |||
| Shares Outstanding | 30 M | |||
| Shares Owned By Insiders | 64.13 % | |||
| Shares Owned By Institutions | 26.24 % | |||
| Price To Book | 6.55 X | |||
| Price To Sales | 8,803 X | |||
| Gross Profit | 52 K | |||
| EBITDA | (56.66 M) | |||
| Net Income | (58.59 M) | |||
| Current Ratio | 15.66 X | |||
| Book Value Per Share | 2.60 X | |||
| Cash Flow From Operations | (55.11 M) | |||
| Earnings Per Share | (1.95) X | |||
| Beta | 0.21 | |||
| Market Capitalization | 359.97 M | |||
| Total Asset | 117.63 M | |||
| Net Asset | 117.63 M |
About Exact Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Exact Therapeutics AS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Exact Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Exact Therapeutics AS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in Exact Stock
Exact Therapeutics financial ratios help investors to determine whether Exact Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Exact with respect to the benefits of owning Exact Therapeutics security.